Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)

v3.23.1
Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Mar. 31, 2023
USD ($)
shares
Nov. 29, 2022
shares
Sep. 01, 2022
USD ($)
Dec. 31, 2021
USD ($)
Mar. 31, 2023
USD ($)
shares
Sep. 30, 2022
USD ($)
shares
Mar. 31, 2022
USD ($)
Mar. 31, 2023
USD ($)
segment
shares
Mar. 31, 2022
USD ($)
Jun. 30, 2022
USD ($)
shares
Number of Operating Segments | segment               2    
Proceeds from Divestiture of Interest in Consolidated Subsidiaries               $ 17,824    
Net sales         $ 294,146   $ 290,376 835,382 $ 817,371  
Gain on sale of Eminence               11,682 $ 0  
Payments to Acquire Investments, Total               $ 232,000    
Common stock, shares authorized (in shares) | shares 400,000,000 400,000,000     400,000,000 100,000,000   400,000,000   400,000,000
Declared stock split   4                
Additional shares | shares   3                
Changzhou Eminence Biotechnology [Member]                    
Proceeds from Divestiture of Interest in Consolidated Subsidiaries     $ 17,800              
Goodwill, Impairment Loss                   $ 8,300
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)                   8,600
Protein Sciences [Member]                    
Pre-tax restructuring charges               $ 800    
Protein Sciences [Member] | Changzhou Eminence Biotechnology [Member]                    
Net sales           $ 2,000       4,600
Diagnostics and Genomics [Member]                    
Pre-tax restructuring charges                   1,400
Wilson Wolf Corporation [Member]                    
Investment percentage 19.90%       19.90%     19.90%    
Investment amount $ 257,000       $ 257,000     $ 257,000    
Payments to Acquire Investments, Total $ 232,000     $ 25,000            
Forward Contract, Milestone, Multiple for Total Expected Payments 4.4       4.4     4.4    
Wilson Wolf Corporation [Member] | First Part of Forward Contract [Member]                    
Forward Contract, Milestone, Annual Revenue Required $ 92,000       $ 92,000     $ 92,000    
Forward Contract, Milestone, Annual EBITDA 55,000       55,000     55,000    
Wilson Wolf Corporation [Member] | Second Part of Forward Contract [Member]                    
Forward Contract, Milestone, Annual Revenue Required 226,000       226,000     226,000    
Forward Contract, Milestone, Annual EBITDA 136,000       136,000     136,000    
Forward Contract, Additional Investment $ 1,000,000       1,000,000     1,000,000    
QT Holdings Corporation [Member] | Protein Sciences [Member]                    
Pre-tax restructuring charges         $ 0     $ 2,200    
Changzhou Eminence Biotechnology [Member]                    
Inventory Write-down                   900
Asset Impairment Charges, Total                   $ 900
Changzhou Eminence Biotechnology [Member] | Nonoperating Income (Expense) [Member]                    
Gain on sale of Eminence           $ 11,700